Vanda Pharmaceuticals | VNDA - 资产



金融业
股票价格
USD
资产
USD 488.95M
现金及等价物
USD 84.85M
销售成本
USD 198.77M
流动资产
USD 347.26M
流动负债
USD 145.16M
债务
USD 4.96M
股息收益率
0
EBIT
USD -10.28M
EBITDA
USD -8.31M
员工
203
EPS每股收益
USD -0.09
股本和储备
USD 327.19M
销售毛利
USD 50.6M
债务利息支出
-1.37B
贷款资金
USD 3.15M
市值
USD 357.3M
净收入
USD -18.9M
营业费用
USD -1.14B
营业利润
USD -40.66M
普通股股本
USD 58K
PE价格收益
16.79
税前利润
USD -22.92M
销售收入
USD 198.77M
销售和管理费用
USD 39.28M
股票
USD 1.85M
贸易债权人
USD 39.09M
应收帐款人
USD 47.1M


资产 更改 日
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Akebia Therapeutics USD 362.52M 14.04M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Insmed USD 2.08B 188.7M 2026-03
J&J USD 200.89B 1.68B 2026-03
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 11.49B 850M 2026-03
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Takeda JPY 15.45T 44.34B 2026-03
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Veracyte USD 1.44B 30.38M 2026-03